Literature DB >> 18494537

Relationship of neurotransmitters to the symptoms of major depressive disorder.

David J Nutt1.   

Abstract

A relationship appears to exist between the 3 main monoamine neurotransmitters in the brain (i.e., dopamine, norepinephrine, and serotonin) and specific symptoms of major depressive disorder. Specific symptoms are associated with the increase or decrease of specific neurotransmitters, which suggests that specific symptoms of depression could be assigned to specific neurochemical mechanisms, and subsequently specific antidepressant drugs could target symptom-specific neurotransmitters. Research on electroconvulsive therapy has supported a correlation between neurotransmitters and depression symptoms. A 2-dimensional model of neurotransmitter functions is discussed that describes depression as a mixture of 2 separate components--negative affect and the loss of positive affect--that can be considered in relation to the 3 amine neurotransmitters. Owing to the different methods of action of available antidepressant agents and the depression symptoms thought to be associated with dopamine, serotonin, and norepinephrine, current treatments can be targeted toward patients' specific symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18494537

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  94 in total

1.  Valerenic Acid Protects Against Physical and Psychological Stress by Reducing the Turnover of Serotonin and Norepinephrine in Mouse Hippocampus-Amygdala Region.

Authors:  Hyo Young Jung; Dae Young Yoo; Sung Min Nam; Jong Whi Kim; Jung Hoon Choi; Miyoung Yoo; Sanghee Lee; Yeo Sung Yoon; In Koo Hwang
Journal:  J Med Food       Date:  2015-07-15       Impact factor: 2.786

2.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 3.  Neural mechanisms of the cognitive model of depression.

Authors:  Seth G Disner; Christopher G Beevers; Emily A P Haigh; Aaron T Beck
Journal:  Nat Rev Neurosci       Date:  2011-07-06       Impact factor: 34.870

4.  Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

5.  Depressive Symptoms and Risk of Postoperative Delirium.

Authors:  Patrick J Smith; Deborah K Attix; B Craig Weldon; Terri G Monk
Journal:  Am J Geriatr Psychiatry       Date:  2016-02-17       Impact factor: 4.105

6.  Extracts of Sideritis scardica as triple monoamine reuptake inhibitors.

Authors:  Rainer Knörle
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

Review 7.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

8.  Protocatechuic acid attenuate depressive-like behavior in olfactory bulbectomized rat model: behavioral and neurobiochemical investigations.

Authors:  Vishnu N Thakare; Rajesh R Patil; Anupama A Suralkar; Valmik D Dhakane; Bhoomika M Patel
Journal:  Metab Brain Dis       Date:  2019-03-08       Impact factor: 3.584

9.  Dopamine D2L Receptor Deficiency Causes Stress Vulnerability through 5-HT1A Receptor Dysfunction in Serotonergic Neurons.

Authors:  Norifumi Shioda; Yoshiki Imai; Yasushi Yabuki; Wataru Sugimoto; Kouya Yamaguchi; Yanyan Wang; Takatoshi Hikida; Toshikuni Sasaoka; Michihiro Mieda; Kohji Fukunaga
Journal:  J Neurosci       Date:  2019-08-01       Impact factor: 6.167

10.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.